版本:
中国

BRIEF-Sangamo Therapeutics updates on SB-525 investigational hemophilia A gene therapy

June 7 Sangamo Therapeutics:

* Sangamo Therapeutics and Pfizer announce that SB-525 investigational hemophilia A gene therapy receives orphan medicinal product designation from the European medicines agency

* Cos also announce Phase 1/2 clinical trial evaluating SB-525 in adults with severe hemophilia A is now open for enrollment

* Sangamo Therapeutics Inc - initial data from study of SB-525 in adults with hemophilia A expected in late 2017 or early 2018 Source text for Eikon: Further company coverage:

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐